Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Albiglutide in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* BMI 20-45kg/m2~Exclusion Criteria:~* NYHA Class II to IV heart failure~* females who are pregnant, lactating, or less than 6 weeks post-partum

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo + pioglitazone (with or without metformin) (Type: PLACEBO_COMPARATOR): Placebo albiglutide weekly injection + pioglitazone (with or without metformin)
- albiglutide + pioglitazone (with or without metformin) (Type: EXPERIMENTAL): albiglutide weekly injection + pioglitazone (with or without meformin)

Based on this trial design, predict the completion outcome and termination type (if applicable).